Ginkgo Bioworks (NYSE:DNA – Get Free Report) and Senti Biosciences (NASDAQ:SNTI – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability and analyst recommendations.
Profitability
This table compares Ginkgo Bioworks and Senti Biosciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Ginkgo Bioworks | -298.78% | -58.54% | -34.24% |
| Senti Biosciences | N/A | -154.84% | -77.42% |
Valuation & Earnings
This table compares Ginkgo Bioworks and Senti Biosciences”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Ginkgo Bioworks | $251.46 million | 2.95 | -$892.87 million | ($13.08) | -0.99 |
| Senti Biosciences | $2.56 million | 8.19 | -$71.06 million | ($15.56) | -0.29 |
Insider and Institutional Ownership
78.6% of Ginkgo Bioworks shares are held by institutional investors. Comparatively, 25.7% of Senti Biosciences shares are held by institutional investors. 9.7% of Ginkgo Bioworks shares are held by company insiders. Comparatively, 15.9% of Senti Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Analyst Ratings
This is a breakdown of current ratings and target prices for Ginkgo Bioworks and Senti Biosciences, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Ginkgo Bioworks | 3 | 1 | 1 | 0 | 1.60 |
| Senti Biosciences | 0 | 0 | 1 | 0 | 3.00 |
Ginkgo Bioworks currently has a consensus price target of $4.58, suggesting a potential downside of 64.50%. Senti Biosciences has a consensus price target of $10.00, suggesting a potential upside of 118.82%. Given Senti Biosciences’ stronger consensus rating and higher possible upside, analysts plainly believe Senti Biosciences is more favorable than Ginkgo Bioworks.
Risk and Volatility
Ginkgo Bioworks has a beta of 1.09, meaning that its share price is 9% more volatile than the S&P 500. Comparatively, Senti Biosciences has a beta of 2.42, meaning that its share price is 142% more volatile than the S&P 500.
Summary
Senti Biosciences beats Ginkgo Bioworks on 8 of the 13 factors compared between the two stocks.
About Ginkgo Bioworks
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
About Senti Biosciences
Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Receive News & Ratings for Ginkgo Bioworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ginkgo Bioworks and related companies with MarketBeat.com's FREE daily email newsletter.
